Pharmos (PARS) is a biotech company that is doing the unimaginable. They are on the brink of profitability. They have two products that are FDA approved, Lotemax and Alrex, which are for the treatment of ocular inflammation and allergy. PARS has a marketing agreement with Bausch & Lomb Pharmaceuticals for sale of Lotemax and Alrex in the US, Canada, and Europe. They are already showing signs of becoming cash cows for the company. In addition, PARS has an interesting pipeline. The Company has another ophthalmic product about to enter Phase III clinical trials, My interest was drawn to PARS because of their Phase II trial results of HU-211 for traumatic head injury. HU-211 is a non-competitive NMDA antagonist that the Phase II results suggest is effective for neuroprotection. The results were excellent and suggest that HU-211 may become a front line treatment for traumatic head injury. There is an active and informative Pharmos thread in the "$5 and Under" category.
Subject 10176
However, PARS is a biotechnology company and discussion of this stock belongs in the biotech category. So, I am opening this thread. |
